skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Nuclear medicine progress report for quarter ending December 31, 1985

Technical Report ·
DOI:https://doi.org/10.2172/5620053· OSTI ID:5620053

The first clinical results with the new iodine-123-labeled methylbranched fatty acid, 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP), are described in this report. A series of 19 patients were evaluated with (I-123)BMIPP by planar imaging studies. The groups consisted of patients with normal coronary arteries, and patients with single-, double-, and triple-vessel disease. The goal of these studies was to evaluate (I-123)BMIPP for the first time in patients, to analyze regional uptake and wash-out properties, and to compare the results of BMIPP with the straight-chain analogue, (I-123)IPP. The results of wash-out kinetic measurements are described in this report. An important finding was that, in addition to good myocardial images, abnormal (reduced) elimination was observed in patients with coronary artery disease (CAD) which is not observed with other agents such as IPP. Thus, the additional information obtained with BMIPP may be of useful prognostic value. The results of methyl-branching on the subcellular distribution and incorporation into lipid pools of rat hearts using analogues of 19-iodo-18-nonadecenoic acid are also described in this report. 15 figs., 3 tabs.

Research Organization:
Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
DOE Contract Number:
AC05-84OR21400
OSTI ID:
5620053
Report Number(s):
ORNL/TM-9937; ON: DE86011345
Resource Relation:
Other Information: Portions of this document are illegible in microfiche products. Original copy available until stock is exhausted
Country of Publication:
United States
Language:
English